Citigroup Raises Buy Rating to $250, Up from $220 PT

Citigroup Raises Buy Rating to $250, Up from $220 PT

Citigroup has initiated coverage on Acadia Pharmaceuticals (ACAD) with a 'Buy' rating and a price target of $33.00, as announced by analyst Yigal Nochomovitz on September 12, 2025. This marks a significant shift in analyst outlook, reflecting continued interest in the biopharmaceutical company from major financial institutions.

The new rating follows a series of price target adjustments from other analysts. For instance, JP Morgan maintained an 'Overweight' rating but lowered the price target from $34.00 to $33.00 on September 29, 2025. Similarly, Needham maintained a 'Buy' rating but lowered the price target from $30.00 to $28.00 on September 24, 2025. These adjustments underscore the varying perspectives among analysts regarding the company's market performance.

Acadia Pharmaceuticals, focused on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases, has two core franchises: neuroscience and neuro-rare diseases. Its neuroscience franchise is anchored by NUPLAZID (pimavanserin), used for treating hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by DAYBUE, used for treating Rett syndrome.

Based on the one-year price targets offered by 18 analysts, the average target price for ACADIA Pharmaceuticals Inc is $28.94, with a high estimate of $40.00 and a low estimate of $17.00. This average target implies an upside of 38.23% from the current price of $20.94. Additionally, the consensus recommendation from 20 brokerage firms is currently 2.3, indicating an "Outperform" status. GuruFocus estimates the GF Value for ACADIA Pharmaceuticals Inc in one year to be $33.72, suggesting an upside of 61.03% from the current price.

Investors are advised to consider these ratings and price targets as part of a broader strategy when evaluating their positions in ACadia Pharmaceuticals. The company's focus on innovative treatments for unmet medical needs positions it as a key player in the biopharmaceutical sector.